CORONA vs KPL: Stock Comparison

Corona Remedies Ltd vs Kwality Pharmaceuticals Ltd

Live data: 28 July 2026, 4:08 PM IST • Source: NSE and company filings

Corona Remedies Ltd is the larger company by market capitalisation. Corona Remedies Ltd shows a higher ROE, a higher dividend yield and lower leverage, while Kwality Pharmaceuticals Ltd shows a lower P/E and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Corona Remedies Ltd and Kwality Pharmaceuticals Ltd on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, CORONA is more favourable on 4 of 13 scored metrics and KPL on 7These counts are context-free and are not an overall rating.

Key Differences

Market Cap
CORONA is the larger company
₹12,654 Cr vs ₹2,692 Cr
P/E Ratio
KPL has a lower P/E
39.83x vs 68.05x
P/B Ratio
KPL has a lower P/B
8.09x vs 16.87x
EPS
KPL has higher earnings per share
₹64.9 vs ₹30.3
Dividend Yield
CORONA has a higher dividend yield
0.49% vs 0%
Qtr Sales Growth
KPL has stronger quarterly sales growth
35.8% vs 20.2%
Qtr Profit Growth
KPL has stronger quarterly profit growth
74.6% vs 43.7%
ROE
CORONA has a higher ROE
29.5% vs 22.8%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Price

MetricCORONAKPL
Live Price₹2,069.7₹2,590.4
Day Change-1.36%-4.34%
Volume23,03126,342
52-Week High₹2,140₹2,890.3
52-Week Low₹1,336.6₹1,561
Distance from 52W High-3.29%-10.38%

Valuation

MetricCORONAKPL
Market Cap₹12,654 Cr₹2,692 Cr
P/E Ratio68.05x39.83x
P/B Ratio16.87x8.09x
EPS₹30.3₹64.9
Book Value₹122₹320
Dividend Yield0.49%0%

Growth

MetricCORONAKPL
Revenue Growth (TTM YoY)0%0%
EPS Growth (TTM YoY)0%0%
Qtr Sales Growth20.2%35.8%
Qtr Profit Growth43.7%74.6%

Profitability & Leverage

MetricCORONAKPL
ROE29.5%22.8%
ROCE33.3%24.2%
Net Margin13.19%13.39%
Operating Margin21%23.5%
Debt to Equity0.22x0.39x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricCORONAKPL
Promoter Holding69%54.87% 0.04 pp
FII Holding3.63% 1.38 pp2.79% 2.29 pp
DII Holding12.9% 5.88 pp0.36% 0.03 pp
Public Holding14.48% 7.26 pp41.98% 2.36 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Corona Remedies Ltd and Kwality Pharmaceuticals Ltd.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.